^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    papaverine

    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    Ca2+ channel antagonist, Mitochondria complex 1 inhibitor, PDE inhibitor, Vasodilator agent
    Related drugs:
    Associations

    News

    Trials
    15d
    Use of Papaverine to Shorten the Second Stage/Duration of Labor in Pregnant Women After Cervical Ripening by Double-balloon Catheter (clinicaltrials.gov)
    P=N/A, N=184, Recruiting, Hillel Yaffe Medical Center
    New trial
    |
    papaverine
    5ms
    Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2028 --> Sep 2028 | Trial primary completion date: Jan 2028 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • oxaliplatin • papaverine
    5ms
    IV PAPAVERINE Prior to Propess for Labor Induction (clinicaltrials.gov)
    P4, N=110, Completed, Western Galilee Hospital-Nahariya | Not yet recruiting --> Completed | Trial completion date: Aug 2026 --> Mar 2025 | Trial primary completion date: Aug 2026 --> Mar 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    papaverine
    5ms
    In vivo, in vitro and in silico evaluation of Rumex nepalensis Spreng. and its active phytoconstituent (Chrysophanol) in gastrointestinal disorders. (PubMed, J Ethnopharmacol)
    The findings suggest that Rumex nepalensis and chrysophanol possess gastroprotective effect, mediating through its anti-H. Pylori, antispasmodic, antioxidants and anti-inflammatory properties. This, provide scientific validation for its traditional use in GIT disorders and highlight its potential as a natural therapeutic candidate.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CAT (Catalase)
    |
    papaverine
    9ms
    Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • papaverine
    10ms
    Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    5-fluorouracil • oxaliplatin • papaverine
    10ms
    Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Suspended --> Recruiting | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment open • Trial completion date • Trial primary completion date
    |
    papaverine
    10ms
    Papaverine in Combination with Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=28, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • papaverine
    1year
    Effects of papaverine on hepatic, splenic and renal hemodynamics in patients after liver transplantation: a randomized controlled trial (ChiCTR2400087258)
    P1, N=62, Completed, Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University
    New P1 trial
    |
    papaverine
    over1year
    IV PAPAVERINE Prior to Propess for Labor Induction (clinicaltrials.gov)
    P4, N=110, Not yet recruiting, Western Galilee Hospital-Nahariya
    New P4 trial
    |
    papaverine
    over1year
    Papaverine and Oxytocin vs Oxytocin Alone in Labor Induction (clinicaltrials.gov)
    P=N/A, N=126, Not yet recruiting, Western Galilee Hospital-Nahariya
    New trial
    |
    papaverine
    over1year
    A randomized controlled study on the effect of abandoning anti-spasmodic drugs after finger replantation on finger survival (ChiCTR2200058130)
    P=N/A, N=144, Recruiting, Subei people's Hospital; Subei people's Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    papaverine